SEC Tracker
Get the app

Artiva Biotherapeutics ARTV

Aslan Fred (Director) plans to sell 12,749 ARTV shares, about $42,072

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Dec 15, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Restricted Stock Units
  4. 10b5-1 plan adopted: Jul 23, 2024

All of Aslan Fred's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Artiva Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  2. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. CalciMedica CALC public float $16M, Jun 30, 2025